Abstracts tagged "prevention"

Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Tiphaine Lenfant¹, Elizabeth Kirchner², Rula Hajj-ali³, Leonard Calabrese³ and Cassandra Calabrese³, ¹Cleveland Clinic Foundation, Rocky River, OH, ²Cleveland Clinic Foundation, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Rebecca Overbury¹, Gregory Stoddard² and Tracy Frech³, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…
Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Victoria Furer¹, Clara Weil², Melanie Orin², Gabriel Chodick², Varda Shalev², Yonit Fisher Shoval³, Raanan Cohen³ and Ori Elkayam⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, ³Abbvie, Hod Hasharon, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…
Abstract Number: 0598 • ACR Convergence 2020
Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality
Shivani Garg¹, Callie Plafkin², Tripti Singh¹, Sarah Panzer³ and Christie Bartels⁴, ¹UW Madison, Madison, WI, ²UW Madison, Madison, ³UW-Madison, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Lupus nephritis (LN) contributes to a 10-fold higher risk to develop kidney failure and 26-fold higher mortality compared to peers. Kidney biopsy remains a…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Kengo Akashi¹, Sadao Jinno ², Akira Onishi ¹, Mai Yamashita ³, Yoko Nose ⁴, Takaichi Okano ¹, Yo Ueda ¹, Sho Sendo ¹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ⁴Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Chelsie Fleischer¹, Marie Feser ², Elizabeth Bemis ³, Christopher Striebich ⁴, LauraKay Moss ⁴, Vasilisa Kormendi ⁵, Sharon White ⁵, V. Michael Holers ⁶, Mark Harrison ⁷ and Kevin Deane ², ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, School of Medicine, Aurora, CO USA, Aurora, CO, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷The University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…
Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Jun Won Park¹, Jeffrey R. Curtis², Hajeong Lee³, Yeong Wook Song⁴ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Linh Truong¹, Nicole Ridolfi¹ and Maida Wong^2,3, ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Department of Medicine, University of California, Irvine, orange, CA, ³Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Anna Molto¹, Adrien Etcheto², Serge Poiraudeau³, Laure Gossec⁴, Pascal Claudepierre⁵, Martin Soubrier⁶, Françoise Fayet⁷, Daniel Wendling⁸, Philippe Gaudin⁹, Emmanuelle Dernis¹⁰, Sandrine Guis¹¹, Sophie Pouplin¹², Adeline Ruyssen-Witrand¹³ and Maxime Dougados¹⁴, ¹Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ²Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, ³Univ. Paris Descartes, PRES Sorbonne Paris, INSERM UMR-S 1153 et Institut fédératif de recherche sur le handicap, Paris, France, Paris, France, ⁴Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁹Grenoble University Hospital, France, Grenoble, France, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹Rheumatology Department, CHU, Marseile, France, ¹²Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹³Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹⁴Paris Descartes University, Hôpital Cochin, Paris, France
Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…
Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Xinyi Liu¹, Cianna Leatherwood¹, Sara K. Tedeschi¹, Medha Barbhaiya², Cameron Speyer¹, Bing Lu³, Karen Costenbader¹, Elizabeth Karlson¹ and Jeffrey A. Sparks¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
Abstract Number: 295 • 2018 ACR/ARHP Annual Meeting
Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
Ann M. Chodara¹, Edmond Ramly^2,3, Douglas White⁴, Heather Johnson⁵, Andrea Gilmore-Bykovskyi⁶ and Christie M. Bartels⁷, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Gundersen Lutheran - Onalaska Clinic, Onalaska, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin School of Nursing, Madison, WI, ⁷Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Smoking remains the leading preventable cause of US mortality and predicts higher incidence, greater severity, and reduced treatment response in many rheumatologic conditions. Despite…
Abstract Number: 344 • 2018 ACR/ARHP Annual Meeting
Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Melissa Swee¹, Jaime Wilson² and Bharat Kumar³, ¹Transplant Nephrology, University of Iowa, Iowa City, IA, ²Iowa City Veterans Affairs Medical Center, Iowa City, IA, ³Internal Medicine-Division of Immunology, University of Iowa, Iowa City, IA
Background/Purpose: Pneumonia is a leading cause of morbidity and mortality in the United States among immunocompromised individuals with rheumatologic diseases. Despite the publication of Advisory…
Abstract Number: 841 • 2017 ACR/ARHP Annual Meeting
Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Masayoshi Harigai^1,2, Masako Utsunomiya^2,3,4, Hiroaki Dobashi⁵, Toshio Odani^6,7, Kazuyoshi Saito^8,9, Naoto Yokogawa¹⁰, Kenji Nagasaka^11,12, Kenchi Takenaka^3,11, Makoto Soejima^11,13, Takahiko Sugihara¹⁴, Hiroyuki Hagiyama¹⁵, Shinya Hirata¹⁶, Kazuo Matsui^17,18, Yoshinori Nonomura¹⁹, Masahiro Kondo²⁰, Fumihito Suzuki^13,21, Makoto Tomita²², Mari Kihara²³, Waka Yokoyama³, Fumio Hirano²⁴, Hayato Yamazaki³, Ryoko Sakai^2,25, Toshihiro Nanki^2,26, Ryuji Koike^2,3, Hitoshi Kohsaka³ and Nobuyuki Miyasaka³, ¹Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Rheumatology, Musashino Red Cross Hospital, Tokyo, Japan, ⁵Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁶Third Department of Internal Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan, ⁷Molecular Physiology and Therapeutics Branch/Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR)/ National Institutes of Health (NIH), Bethesda, MD, ⁸Tobata General Hospital, Fukuoka, Japan, ⁹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹¹Department of Rheumatology, Ome Municipal General Hospital, Tokyo, Japan, ¹²Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University, Tokyo, Japan, ¹³Department of Rheumatology, Soka Municipal Hospital, Saitama, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Department of Rheumatology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan, ¹⁶Department of Hematology, Rheumatology, and Infectious Disease, Kumamoto University, Kumamoto, Japan, ¹⁷Department of Rheumatology, Kameda Medical Center, Chiba, Japan, ¹⁸Department of Internal Medicine, Takikawa Municipal Hospital, Hokkaido, Japan, ¹⁹Department of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan, ²⁰Department of Rheumatology, Faculty of Medicine, Shimane University, Shimane, Japan, ²¹Department of Rheumatology, JA Toride Medical Center, Ibaraki, Japan, ²²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ²³Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ²⁴Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²⁵Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²⁶Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PCP), but is sometimes discontinued due to adverse events (AEs). We have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].